ReviewInfectious disorders drug targets2019
PZQ Therapy: How Close are we in the Development of Effective Alternative Anti-schistosomal Drugs?
Review in Infectious disorders drug targets, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Plant-Derived Terpenes as Emerging Therapeutics Against Schistosomiasis.International journal of molecular sciences · 2026Review
- Review
- Considering ivermectin for treatment of schistosomiasis.Parasitology research · 2024Article
- Diterpenoids with Schistosomula-Killing and Anti-Fibrosis Activities In Vitro from the Leaves ofMolecules (Basel, Switzerland) · 2024Article
- Katayama syndrome disguised as eosinophilic asthma with acute systemic symptoms and pulmonary nodules.Respiratory medicine case reports · 2024Article
- Nanomaterials as a Potential Target for Infectious Parasitic Agents.Current drug delivery · 2024Review
- Therapeutic and vaccinomic potential of moonlighting proteins for the discovery and design of drugs and vaccines against schistosomiasis.American journal of translational research · 2024Review
- Plumbagin: A Promising In Vivo Antiparasitic Candidate againstBiomedicines · 2023Article
- Advances in new target molecules against schistosomiasis: A comprehensive discussion of physiological structure and nutrient intake.PLoS pathogens · 2023Review
- A Critical Review on Human Malaria and Schistosomiasis Vaccines: Current State, Recent Advancements, and Developments.Vaccines · 2023Review
- In Vivo Evaluation of Praziquantel-Loaded Solid Lipid Nanoparticles againstInternational journal of molecular sciences · 2022Article
- In Vivo Evaluation of an Antibody-Functionalized Lipoidal Nanosystem for Schistosomiasis Intervention.Pharmaceutics · 2022Article
- Recombinant Expression and Biophysical Characterization of a DruggableAdvanced pharmaceutical bulletin · 2022Article
- Bioorganometallic Compounds as Novel Drug Targets against Schistosomiasis in Sub-Saharan Africa: An alternative to Praziquantel?Advanced pharmaceutical bulletin · 2022Review
- Review
- Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools.Journal of enzyme inhibition and medicinal chemistry · 2020Article
- A Review of Nanotechnology for Targeted Anti-schistosomal Therapy.Frontiers in bioengineering and biotechnology · 2020Review
- The Effect of Climate Change and the Snail-Schistosome Cycle in Transmission and Bio-Control of Schistosomiasis in Sub-Saharan Africa.International journal of environmental research and public health · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today schistosomiasis, caused mainly by the three major schistosome species (S. mansoni, S. haematobium and S. japonicum), has for many decades and still continues to be on a rapid and swift rise globally, claiming thousands of lives every year and leaving 800 million people at the risk of infection. Due to the high prevalence of this disease and the steady increase in the infection rates, praziquantel (PZQ) remains the only effective drug against this acute disease although it has no effect on the juvenile schistosome parasite. However, no significant approaches have been made in recent years in the discovery of new or alternative drugs and unfortunately, resistance to this drug has been reported in some parts of the world. Therefore, it is imperative to develop a new drug for this debilitating disease. In this review, a brief history of past, present, and new promising anti-schistosomal drugs is presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.